News

Pooled results from two randomized, investigator-masked parallel group clinical trials show that the fixed combination fo brimonidine tartrate 0.2%-timolol maleate 0.5% produced greater IOP lowering than the fixed combination of dorzolamidehydrochloride 2%-timolol maleate 0.5%, whether the fixed combination products were used alone or as an adjunct to treatment with a prostaglandin analogue.

Timolol maleate 0.5%/sorbitol complex is a convenient, well-tolerated choice for adjunctive therapy in patients taking a prostaglandin analogue who need further IOP control.

Good physicians can serve their patients best by adopting behaviors that might be different from their normal attributes in the rest of their lives.

Switching to another prostaglandin analogue that does not contain benzalkonium chloride may not be the answer for managing complaints from patients of dryness and irritation.

TLC Vision Corp. has won U.S. bankruptcy court approval for a restructuring of its debt.

A handheld applanation tonometer is a newer portable device for measuring IOP that has been designed for reliable performance and easy, economical use.

In response to an FDA warning of cleaning validation at one of its plants, Abbott Medical Optics said problematic manufacturing processes were restricted to production of its ophthalmic viscosurgical device, 3% sodium hyaluronate, which is no longer being made or sold.

Glaucoma specialists are beginning to realize that much of the conventional wisdom surrounding angle-closure glaucoma is incorrect.

Alpha adrenoceptor agonist therapy using brimonidine tartrate 0.1% with a preservative has a wide spectrum of uses in the management of ocular hypertension and glaucoma.

Novartis plans to assume complete control over Alcon Laboratories in a two-step process that some analysts and some members of Alcon's board of directors are challenging for its fairness under U.S. and Swiss merger laws.

Glaucoma and ocular hypertension can effectively be treated topically with IOP-lowering drops.

In his work, Mr. De Gennaro is often asked to review optical dispensary financial statements, which reveal much about how efficiently a dispensary runs as a business.

A new auto tonometer with corneal response technology features corneal compensated IOP, a pressure measurement significantly less affected by the cornea than with other methods of tonometry.

A dentist, aged 48 years, was referred for evaluation and management of loss of correctable acuity, disabling glare, and loss of binocular stereopsis following a series of complicated surgical procedures in his left eye.

Results of a published case series reaffirm the safety of magnetic resonance imaging studies in patients with miniature glaucoma shunt.

The latest generation of photochromic lenses is designed to deliver a combination of high performance and compatibility with all premium lens materials.

InSite Vision Inc. has announced plans to study ISV-303, a topical anti-inflammatory product intended to reduce the pain and swelling associated with ocular surgery, in clinical trials pending the completion of investigational new drug-enabling toxicology studies in the first half of this year.

ThromboGenics NV expects to present the results of two phase III trials evaluating microplasmin for the non-surgical treatment of eye disease later this year.

The Foundation of the American Academy of Ophthalmology, the fundraising arm of the AAO, is celebrating its 30th anniversary this year, as is its first program, the Museum of Vision. EyeCare America, a public service program of the foundation, is marking its 25th anniversary.

BTG plc has licensed to Allergan exclusive worldwide rights to develop products for eye diseases and conditions using BTG's drug delivery system (ReGel).

Gregory L. Skuta, MD, has been named president and chief executive officer (CEO) of the Dean McGee Eye Institute, succeeding David W. Parke II, MD, who was appointed executive vice president and CEO of the American Academy of Ophthalmology in San Francisco in 2009.

Tom Hejkal, MD, PhD, became the McGaw Memorial Chairman of the Department of Ophthalmology and Visual Sciences at University of Nebraska Medical Center on Dec. 1.

ISTA Pharmaceuticals Inc. has submitted a supplemental new drug application to the FDA for bromfenac ophthalmic solution dosed once-daily as a treatment for ocular inflammation and pain following cataract surgery.

Bausch & Lomb has announced the launch of the first aberration-free accommodating IOL with aspheric optics (Crystalens AO) to cataract surgeons worldwide.

Alcon Laboratories Inc. plans to acquire Optonol Ltd. by the end of first quarter.

TLC Vision Corp. and two of its wholly owned subsidiaries, TLC Vision (USA) Corp. and TLC Management Services, are restructuring their debt through a pre-arranged Chapter 11 bankruptcy proceeding.

Novartis AG has exercised its option to purchase the remaining shares in Alcon Laboratories Inc. owned by Nestle S.A. at a weighted average price of $180 per share in cash, according to prepared statement from Alcon.

An angle-supported phakic lens had a minimal effect on corneal endothelial cell health in patients followed up to 4 years after implantation.